Trinity Biotech, the Nasdaq-listed biotechnology company which is taking a secondary listing on the Irish stock market, has reported strong profit growth for the first quarter of the year.

After-tax profits doubled to $902,000 (€848,222) while earnings before interest, tax and depreciation more than doubled to $1.4 million. Sales in the period rose from $5.5 million to $6.4 million. Trinity chief financial officer Mr Jonathan O'Connell said the increase in turnover came despite the sale of the group's $6 million over-the-counter pregnancy test business.